From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

By C. Hartinger, Stefanie Zorbas-Seifried, M. Jakupec, B. Kynast, H. Zorbas, B. Keppler. Journal of Inorganic Biochemistry, 2006

865 citations recorded by the source corpus.

Subfields: Materials Chemistry, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/fa5df1d3ead41550da51ce19233ad92747a74368